Periodic Reporting for period 1 - VOILA (Validation of Innovative Lipopeptide Antibiotics)
Berichtszeitraum: 2019-04-01 bis 2021-03-31
The ERC proof of concept (PoC) project titled "Validation Of Innovative Lipopeptide Antibiotics" (acronym VOILA) involved the further development of a novel class of semisynthetic lipopeptide antibiotics recently discovered by researchers at Leiden University. These new lipopeptide antibiotics demonstrate dramatically enhanced activities compared with clinically used antibiotics like vancomycin, one of the most frequently prescribed glycopeptide antibiotics. Notably, these new antibiotics are highly active against drug resistant bacteria including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE). Importantly, the studies conducted as part of this ERC-PoC project demonstrated that the new lipopeptide antibiotics are highly effective in advanced in vivo infection models. These findings support the further pre-clincial development of these promising new antibiotic agents.